LEAP-004 study shows combination of lenvatinib, pembrolizumab is active in these patients.
-
ESMO 2020 — A new combination for advanced melanoma progressing on anti-PD-L1 -
ESMO 2020 — Immunotherapy after prior ICIs in clinical trials: what's the outcome? How effective is follow-up immunotherapy after prior ICI exposure?
-
Fatal pediatric melanoma: clinical subtypes and presentations are diverse All fatal cases of spitzoid melanoma were diagnosed in adolescents.
-
Melanoma: adjuvant dabrafenib, trametinib combination confers durable response 5-year relapse-free survival was superior in phase 3 COMBI-AD trial.
-
Melanoma experts do not recommend routine gene profiling Meta-analysis suggests GEP poorly identifies recurrence in patients with stage I melanoma.
-
Cancer: immunotherapy benefit is independent of sex, age, or performance status Meta-analysis of 37 clinical trials.
-
Adult patients with atopic dermatitis using topical calcineurin inhibitors do not show increased risk of keratinocyte carcinoma.
-
Skin cancer diagnoses in the UK during the COVID-19 pandemic Analysis of data from the Northern Cancer Network.
-
NGFR-expressing melanoma cells were also resistant to BRAF and MEK inhibitors.
-
FDA approves triple therapy for advanced melanoma The approval is based on the phase 3 IMspire150 trial.
-
FDA approves triple drug combo for melanoma The approval is based on the phase 3 IMspire150 trial.
-
Melanoma with brain mets: survival has improved with treatment advances Findings from a Canadian population-based cohort study.
-
Melanoma advances improved OS in patients with brain mets Findings from a Canadian population-based cohort study.
-
COVID-19 has disrupted cancer care across the globe Diagnosis, treatment, funding are all greatly affected.